Skip to main content
SpringerLink
Log in
Book cover

Vitamin D in Chronic Kidney Disease pp 305–319Cite as

Vitamin D and Inflammation in Chronic Kidney Disease

  • Chapter
  • First Online:

  • 883 Accesses

Abstract

Vitamin D deficiency, defined by low serum levels of 25-hydroxyvitamin D, is prevalent in patients with chronic kidney disease, a disorder characterized by a state of chronic low-grade inflammation. This inflammatory state is especially marked in end-stage renal disease and it has been disclosed as an important factor contributing to the progression of renal disease and the high cardiovascular morbidity and mortality found in these patients. This chapter highlights clinical and experimental studies that could potentially explain the link between vitamin D and inflammation. Whether correction of vitamin D deficiency and the associated improvement of inflammatory markers has beneficial effects on cardiovascular outcomes should be investigated in controlled clinical trials.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Lo W-K. Serum parameters, inflammation, renal function and patient outcome. Contrib Nephrol. 2006;150:152–5.

    Article  PubMed  Google Scholar 

  2. Gouni-Berthold I, Krone W, Berthold HK. Vitamin D and cardiovascular disease. Curr Vasc Pharmacol. 2009;7(3):414–22.

    Article  CAS  PubMed  Google Scholar 

  3. Guillot X, Semerano L, Saidenberg-Kermanac’h N, Falgarone G, Boissier M-C. Vitamin D and inflammation. Joint Bone Spine. 2010;77(6):552–7.

    Article  CAS  PubMed  Google Scholar 

  4. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289(1):F8–28.

    Article  CAS  PubMed  Google Scholar 

  5. Al-Badr W, Martin KJ. Vitamin D and kidney disease. Clin J Am Soc Nephrol. 2008;3(5):1555–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–3.

    Article  CAS  PubMed  Google Scholar 

  7. Saggese G, Federico G, Balestri M, Toniolo A. Calcitriol inhibits the PHA-induced production of IL-2 and IFN-gamma and the proliferation of human peripheral blood leukocytes while enhancing the surface expression of HLA class II molecules. J Endocrinol Invest. 1989;12(5):329–35.

    Article  CAS  PubMed  Google Scholar 

  8. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2006;17(12):3382–93.

    Article  CAS  PubMed  Google Scholar 

  9. Wu-Wong JR, Nakane M, Ma J. Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells. Thromb Res. 2006;118(6):709–14.

    Article  CAS  PubMed  Google Scholar 

  10. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int US. 2008;73(2):163–71.

    Article  CAS  Google Scholar 

  11. Li YC, Kong J, Wei M, Chen Z-F, Liu SQ, Cao L-P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest US. 2002;110(2):229–38.

    Article  CAS  Google Scholar 

  12. Artaza JN, Norris KC. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol Engl. 2009;200(2):207–21.

    Article  CAS  Google Scholar 

  13. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev. 2005;10(2):94–111.

    PubMed  Google Scholar 

  14. Liu LC, Voors AA, van Veldhuisen DJ, van der Veer E, Belonje AM, Szymanski MK, et al. Vitamin D status and outcomes in heart failure patients. Eur J Heart Fail. 2011;13(6):619–25.

    Article  CAS  PubMed  Google Scholar 

  15. Björkhem-Bergman L, Nylén H, Norlin AC, Lindh JD, Ekström L, Eliasson E, et al. Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study. Drug Metab Dispos. 2013;41(4):704–8.

    Article  PubMed  CAS  Google Scholar 

  16. Hopkins MH, Owen J, Ahearn T, Fedirko V, Flanders WD, Jones DP, et al. Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial. Cancer Prev Res (Phila). 2011;4(10):1645–54.

    Article  CAS  Google Scholar 

  17. Petchey WG, Johnson DW, Isbel NM. Shining D’ light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D. Nephrology (Carlton). 2011;16(4):351–67.

    Article  CAS  Google Scholar 

  18. Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009;24(8):1445–52.

    Article  PubMed  Google Scholar 

  19. Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant Engl. 2002;17 Suppl 8:29–40.

    Article  CAS  Google Scholar 

  20. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55(2):648–58.

    Article  CAS  PubMed  Google Scholar 

  21. Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int. 2002;62(5):1791–8.

    Article  PubMed  Google Scholar 

  22. Machowska A, Carrero JJ, Lindholm B, Stenvinkel P. Therapeutics targeting persistent inflammation in chronic kidney disease. Transl Res. 2015. doi:10.1016/j.trsl.2015.06.012. pii: S1931-5244(15)00217-0, [Epub ahead of print].

    PubMed  Google Scholar 

  23. Stenvinkel P, Larsson TE. Chronic kidney disease: a clinical model of premature aging. Am J Kidney Dis. 2013;62(2):339–51.

    Article  PubMed  Google Scholar 

  24. Hiramoto JS, Katz R, Peralta CA, Ix JH, Fried L, Cushman M, et al. Inflammation and coagulation markers and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2012;60(2):225–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant. 2006;21(7):1915–20. Epub 2006 Mar 22.

    Article  CAS  PubMed  Google Scholar 

  26. Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol. 2006;17(12 Suppl 3):S169–73.

    Article  CAS  PubMed  Google Scholar 

  27. Meuwese CL, Stenvinkel P, Dekker FW, Carrero JJ. Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol. 2011;7(3):166–76.

    Article  CAS  PubMed  Google Scholar 

  28. Meuwese CL, Snaedal S, Halbesma N, Stenvinkel P, Dekker FW, Qureshi AR, et al. Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-alpha are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant. 2011;26(4):1313–8.

    Article  CAS  PubMed  Google Scholar 

  29. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519–30.

    Article  CAS  PubMed  Google Scholar 

  30. Querfeld U, Mak RH. Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window. Pediatr Nephrol. 2010;25(12):2413–30.

    Article  PubMed  Google Scholar 

  31. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167(11):1159–65.

    Article  CAS  PubMed  Google Scholar 

  32. Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol. 2008;102(11):1540–4.

    Article  CAS  PubMed  Google Scholar 

  33. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol. 1990;19(3):559–63.

    Article  CAS  PubMed  Google Scholar 

  34. Kojima G, Bell C, Abbott RD, Launer L, Chen R, Motonaga H, et al. Low dietary vitamin D predicts 34-year incident stroke: the Honolulu Heart Program. Stroke. 2012;43(8):2163–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168(11):1174–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–11.

    Article  CAS  PubMed  Google Scholar 

  37. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340–9.

    Article  CAS  PubMed  Google Scholar 

  38. Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension. 2011;57(1):63–9.

    Article  CAS  PubMed  Google Scholar 

  39. Kalkwarf HJ, Denburg MR, Strife CF, Zemel BS, Foerster DL, Wetzsteon RJ, et al. Vitamin D deficiency is common in children and adolescents with chronic kidney disease. Kidney Int. 2012;81(7):690–7.

    Article  CAS  PubMed  Google Scholar 

  40. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288(1):E125–32.

    Article  CAS  PubMed  Google Scholar 

  41. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A. 2007;104(43):16810–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Mizobuchi M, Nakamura H, Tokumoto M, Finch J, Morrissey J, Liapis H, et al. Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol. 2010;121(1–2):188–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Koleganova N, Piecha G, Ritz E, Gross ML. Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol Dial Transplant. 2009;24(3):778–87.

    Article  CAS  PubMed  Google Scholar 

  44. Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract. 2006;102(1):c21–9.

    Article  PubMed  Google Scholar 

  45. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010;5(5):905–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Bucharles S, Barberato SH, Stinghen AE, Gruber B, Piekala L, Dambiski AC, et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Ren Nutr. 2012;22(2):284–91.

    Article  CAS  PubMed  Google Scholar 

  47. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol. 2010;21:353–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ogawa T, Kyono A, Sato M, Sugimoto H, Otsuka K, Nitta K. Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients. Clin Exp Nephrol. 2012;16(5):779–85.

    Article  CAS  PubMed  Google Scholar 

  49. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674–84.

    Article  CAS  PubMed  Google Scholar 

  50. Wu-Wong JR. Vitamin D, receptor: a highly versatile nuclear receptor. Kidney Int. 2007;72(3):237–9.

    Article  CAS  PubMed  Google Scholar 

  51. Nemere I, Schwartz Z, Pedrozo H, Sylvia VL, Dean DD, Boyan BD. Identification of a membrane receptor for 1,25-dihydroxyvitamin D3 which mediates rapid activation of protein kinase C. J Bone Miner Res. 1998;13(9):1353–9.

    Article  CAS  PubMed  Google Scholar 

  52. Marcinkowska E. A run for a membrane vitamin D receptor. Biol Signals Recept. 2001;10(6):341–9.

    Article  CAS  PubMed  Google Scholar 

  53. Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res. 2003;164:29–42.

    Article  CAS  PubMed  Google Scholar 

  54. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29(6):726–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr. 2008;88(2):491S–9.

    CAS  PubMed  Google Scholar 

  56. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl. 2002;80:99–102.

    Article  PubMed  Google Scholar 

  57. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM England. 2002;95(12):787–96.

    Article  CAS  Google Scholar 

  58. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008;52(2):249–55.

    Article  CAS  PubMed  Google Scholar 

  59. Provvedini DM, Manolagas SC. 1 Alpha,25-dihydroxyvitamin D3 receptor distribution and effects in subpopulations of normal human T lymphocytes. J Clin Endocrinol Metab. 1989;68(4):774–9.

    Article  CAS  PubMed  Google Scholar 

  60. Tsoukas CD, Provvedini DM, Manolagas SC. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science. 1984;224(4656):1438–40.

    Article  CAS  PubMed  Google Scholar 

  61. Norman PE, Powell JT. Vitamin D and cardiovascular disease. Circ Res. 2014;114(2):379–93.

    Article  CAS  PubMed  Google Scholar 

  62. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys. 2000;374(2):334–8.

    Article  CAS  PubMed  Google Scholar 

  63. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000;164(5):2405–11.

    Article  CAS  PubMed  Google Scholar 

  64. Yu XP, Mocharla H, Hustmyer FG, Manolagas SC. Vitamin D receptor expression in human lymphocytes. Signal requirements and characterization by western blots and DNA sequencing. J Biol Chem. 1991;266(12):7588–95.

    CAS  PubMed  Google Scholar 

  65. Hewison M, Freeman L, Hughes SV, Evans KN, Bland R, Eliopoulos AG, et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol. 2003;170(11):5382–90.

    Article  CAS  PubMed  Google Scholar 

  66. Kizaki M, Norman AW, Bishop JE, Lin CW, Karmakar A, Koeffler HP. 1,25-Dihydroxyvitamin D3 receptor RNA: expression in hematopoietic cells. Blood. 1991;77(6):1238–47.

    CAS  PubMed  Google Scholar 

  67. Seibert E, Levin NW, Kuhlmann MK. Immunomodulating effects of vitamin D analogs in hemodialysis patients. Hemodial Int. 2005;9 Suppl 1:S25–9.

    Article  PubMed  Google Scholar 

  68. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005;97(1–2):93–101.

    Article  PubMed  CAS  Google Scholar 

  69. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med. 2002;8(4):174–9.

    Article  CAS  PubMed  Google Scholar 

  70. Helming L, Bose J, Ehrchen J, Schiebe S, Frahm T, Geffers R, et al. 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood. 2005;106(13):4351–8.

    Article  CAS  PubMed  Google Scholar 

  71. Navarro-Gonzalez JF, Mora-Fernandez C, Muros M, Herrera H, Garcia J. Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. Clin J Am Soc Nephrol. 2009;4(10):1646–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008;74(11):1394–402.

    Article  CAS  PubMed  Google Scholar 

  73. Dusso A, Arcidiacono MV, Yang J, Tokumoto M. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol. 2010;121(1–2):193–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2007;50(1):69–77.

    Article  PubMed  CAS  Google Scholar 

  75. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.

    Article  PubMed  Google Scholar 

  76. Isakova T, Gutierrez OM, Patel NM, Andress DL, Wolf M, Levin A. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr. 2011;21(4):295–302.

    Article  CAS  PubMed  Google Scholar 

  77. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (Lond Engl). 2010;376(9752):1543–51.

    Article  CAS  Google Scholar 

  78. Liu L-J, Lv J-C, Shi S-F, Chen Y-Q, Zhang H, Wang H-Y. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2012;59(1):67–74.

    Article  CAS  PubMed  Google Scholar 

  79. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol. 2008;19(9):1741–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Li YC, Kong J, Wei M, Chen Z-F, Liu SQ, Cao L-P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Heaney RP, Holick MF. Why the IOM recommendations for vitamin D are deficient. J Bone Miner Res. 2011;26(3):455–7.

    Article  CAS  PubMed  Google Scholar 

  82. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis US; 2005;45(4 Suppl 3):S1–153.

    Google Scholar 

  83. Pilz S, Tomaschitz A, Ritz E, Pieber TR. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol. 2009;6(10):621–30.

    Article  CAS  PubMed  Google Scholar 

  84. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CAJ, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16(4):1115–25.

    Article  CAS  PubMed  Google Scholar 

  85. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771–80.

    Article  CAS  PubMed  Google Scholar 

  86. Young EW, Albert JM, Akiba T, et al. Vitamin D therapy and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2005;16:278A.

    Google Scholar 

  87. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446–56.

    Article  CAS  PubMed  Google Scholar 

  88. Perez-Gomez MV, Ortiz-Arduan A, Lorenzo-Sellares V. Vitamin D and proteinuria: a critical review of molecular bases and clinical experience. Nefrologia. 2013;33(5):716–26.

    PubMed  Google Scholar 

  89. Tan X, He W, Liu Y. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int. 2009;76(12):1248–57.

    Article  CAS  PubMed  Google Scholar 

  90. Andress DL. Vitamin D, treatment in chronic kidney disease. Semin Dial. 2005;18(4):315–21.

    Article  PubMed  Google Scholar 

  91. Hudson JQ. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies. Ann Pharmacother. 2006;40(9):1584–93.

    Article  CAS  PubMed  Google Scholar 

  92. Brancaccio D, Bommer J, Coyne D. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies. Drugs NZ. 2007;67(14):1981–98.

    Article  CAS  Google Scholar 

  93. Eleftheriadis T, Antoniadi G, Liakopoulos V, Stefanidis I, Galaktidou G. Inverse association of serum 25-hydroxyvitamin D with markers of inflammation and suppression of osteoclastic activity in hemodialysis patients. Iran J Kidney Dis. 2012;6(2):129–35.

    PubMed  Google Scholar 

  94. Muller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine. 1992;4(6):506–12.

    Article  CAS  PubMed  Google Scholar 

  95. Panichi V, De Pietro S, Andreini B, Bianchi AM, Migliori M, Taccola D, et al. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int. 1998;54(5):1463–9.

    Article  CAS  PubMed  Google Scholar 

  96. Bellows CG, Reimers SM, Heersche JN. Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3. Cell Tissue Res. 1999;297(2):249–59.

    Article  CAS  PubMed  Google Scholar 

  97. Drissi H, Pouliot A, Koolloos C, Stein JL, Lian JB, Stein GS, et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res. 2002;274(2):323–33.

    Article  CAS  PubMed  Google Scholar 

  98. Aihara K, Azuma H, Akaike M, Ikeda Y, Yamashita M, Sudo T, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem. 2004;279(34):35798–802.

    Article  CAS  PubMed  Google Scholar 

  99. Wu-Wong JR, Nakane M, Traylor L, Ruan X, Kroeger PE, Tian J. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs? Curr Opin Investig Drugs. 2005;6(3):245–54.

    CAS  PubMed  Google Scholar 

  100. Husain K, Suarez E, Isidro A, Hernandez W, Ferder L. Effect of paricalcitol and enalapril on renal inflammation/oxidative stress in atherosclerosis. World J Biol Chem. 2015;6(3):240–8.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Moe SM, Zekonis M, Harezlak J, Ambrosius WT, Gassensmith CM, Murphy CL, et al. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis. 2001;38(4):792–802.

    Article  CAS  PubMed  Google Scholar 

  102. Sochorova K, Budinsky V, Rozkova D, Tobiasova Z, Dusilova-Sulkova S, Spisek R, et al. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol. 2009;133(1):69–77.

    Article  CAS  PubMed  Google Scholar 

  103. Izquierdo MJ, Cavia M, Muniz P, de Francisco ALM, Arias M, Santos J, et al. Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. BMC Nephrol. 2012;13:159.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Navarro-Gonzalez JF, Donate-Correa J, Mendez ML, de Fuentes MM, Garcia-Perez J, Mora-Fernandez C. Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study. J Clin Pharmacol. 2013;53(4):421–6.

    Article  PubMed  Google Scholar 

  105. Donate-Correa J, Dominguez-Pimentel V, Mendez-Perez ML, Muros-de-Fuentes M, Mora-Fernandez C, Martin-Nunez E, et al. Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease. Mediators Inflamm. 2014;2014:670475.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Guerrero F, Montes de Oca A, Aguilera-Tejero E, Zafra R, Rodriguez M, Lopez I. The effect of vitamin D derivatives on vascular calcification associated with inflammation. Nephrol Dial Transplant. 2012;27(6):2206–12.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Unit, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain

    Javier Donate-Correa PhD & Ernesto Martín-Núñez

  2. Research Unit and Nephrology Service, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain

    Juan F. Navarro-González MD, PhD, FASN

Authors
  1. Javier Donate-Correa PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ernesto Martín-Núñez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan F. Navarro-González MD, PhD, FASN
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javier Donate-Correa PhD .

Editor information

Editors and Affiliations

  1. Ramsay-Générale de Santé, Clinique du Landy, Saint Ouen, France

    Pablo A. Ureña Torres

  2. San Paolo Hospital, DiSS University of Milan, Milan, Italy

    Mario Cozzolino

  3. VU University Medical Center, Amsterdam, The Netherlands

    Marc G. Vervloet

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Donate-Correa, J., Martín-Núñez, E., Navarro-González, J.F. (2016). Vitamin D and Inflammation in Chronic Kidney Disease. In: Ureña Torres, P., Cozzolino, M., Vervloet, M. (eds) Vitamin D in Chronic Kidney Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-32507-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32507-1_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-32505-7

  • Online ISBN: 978-3-319-32507-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation